Elena Castro, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    06/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    06/13/2022
Return to Curso en vivo de avances globales en cáncer de próstata: el rol de las pruebas genéticas y los inhibidores de PARP (2022) - Espanol